[Heart or heart-lung transplantation and toxoplasmosis].
Among all organ transplantations, those of heart or heart-lung carry the greatest risk of toxoplasmosis. The disease is observed mainly when the donor is seropositive and the recipient seronegative. In these mismatched couples the risk may be as high as 57 percent. Cardiac tissue transplants are responsible for most contaminations. A subclinical serological reactivation can be observed in seropositive recipients. Patent forms are associated with seroconversion in seronegative subjects. Toxoplasmosis is often severe with multivisceral foci; interstitial pneumonia is possible. The serological diagnosis is easy in cases with significant antibody movements, but it may be difficult if the titre is low or stable. The parasitological diagnosis rests on the isolation of toxoplasma in blood, cerebrospinal fluid, bronchoalveolar lavage fluid and cardiac or cerebral biopsy. Immune defence against toxoplasmosis is primarily cellular, with lymphocytosis and inversion of the CD4/CD8 ratio. Macrophages play a crucial role. Interferon-gamma is the major mediator of cellular resistance. In spite of its immunosuppressive action, cyclosporin clearly has an antiparasitic action in vitro and in vivo. A cytomegalovirus infection might facilitate toxoplasma reactivation. Prevention of toxoplasmosis in transplant recipients includes systematic serology of the recipient and, if possible, the donor, detection of mismatched couples and systematic treatment with pyrimethamine of recipients at risk (in seronegative recipients, this drug has reduced the risk from 57 to 14 percent). Cyclosporin should be used as immunosuppressant in preference to other drugs of this kind. Corticosteroids administered in rejections increase the risk of toxoplasmosis.
Couvreur
J
J
Service de Pneumologie infantile, Hôpital Trousseau, Paris.
Tournier
G
G
Sardet-Frismand
A
A
Fauroux
B
B
D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology; D004359:Drug Therapy, Combination; D016027:Heart Transplantation / Q000009:adverse effects*; D016041:Heart-Lung Transplantation / Q000009:adverse effects*; D006801:Humans; D007111:Immunity, Cellular; D011739:Pyrimethamine / Q000627:therapeutic use; D012307:Risk Factors; D012698:Serologic Tests; D013411:Sulfadiazine / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology
D013411:Sulfadiazine; D016572:Cyclosporine; D011739:Pyrimethamine
Transplantation cardiaque ou cardio-pulmonaire et toxoplasmose.